<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02003703</url>
  </required_header>
  <id_info>
    <org_study_id>45/2012</org_study_id>
    <nct_id>NCT02003703</nct_id>
  </id_info>
  <brief_title>Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV .</brief_title>
  <acronym>CORE-HIV</acronym>
  <official_title>Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV : A Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad de Valparaiso</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aclin Laboratories, Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad de Valparaiso</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis B virus infection is a common occurrence among patients with HIV. Effective
      vaccines are available, but there's some uncertainty regarding specific dosages, specially
      among those who have not responded to an initial vaccination. The purpose of this study is to
      determine the effectiveness of a simplified immunization schedule compared to a high-dose
      one.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serologic Response</measure>
    <time_frame>4-8 weeks After Exposure</time_frame>
    <description>Number of participants with positive hepatitis B surface antigen (HBsAg) antibodies 4 to 8 weeks after completion of the vaccination schemes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local Reactions to Vaccine</measure>
    <time_frame>One Week after Exposure</time_frame>
    <description>Number of participants presenting dermatologic reactions to the vaccine up to one week after exposure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Reactions to the Vaccine</measure>
    <time_frame>One Week after Exposure</time_frame>
    <description>Number of participants presenting any systemic adverse reaction attributable to vaccination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hepatitis B</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Recombinant Hepatitis B Virus Vaccine (High Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients allocated to this arm will receive three doses of 40mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recombinant Hepatitis B Virus Vaccine (Standard Dose)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients allocated to this arm will receive three doses of 20mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Hepatitis B Virus Vaccine</intervention_name>
    <arm_group_label>Recombinant Hepatitis B Virus Vaccine (High Dose)</arm_group_label>
    <arm_group_label>Recombinant Hepatitis B Virus Vaccine (Standard Dose)</arm_group_label>
    <other_name>Engerix B (GlaxoSmithKline)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Older than 18 years of age.

          -  Patients infected with Human Immunodeficiency Virus (HIV)

          -  Failed previous vaccination with a standard dose scheme of recombinant hepatitis B
             vaccine (20mcg at 0, 1 and 6 months). Nonresponders will be considered as those
             patients presenting a hepatitis B surface antigen antibody titer lower than 10UI/mL 4
             to 8 weeks after the last dose of the vaccine.

          -  Provision of informed consent.

        Exclusion Criteria:

          -  Proven Hepatitis B virus infection (acute or chronic).

          -  Proven hypersensitivity to the vaccine or any of its components.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Fuster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Gustavo Fricke, Viña del Mar, Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose I Vargas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Escuela de Medicina, Universidad de Valparaíso, Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniela Jensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Escuela de Medicina, Universidad de Valparaíso</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felipe T Martinez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Investigaciones Biomédicas, Escuela de Medicina, Universidad de Valparaíso</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose I Vargas, MD</last_name>
    <phone>62473415</phone>
    <phone_ext>+56 9</phone_ext>
    <email>jivargasd@icloud.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniela Jensen, MD</last_name>
    <phone>62473409</phone>
    <phone_ext>+56 9</phone_ext>
    <email>daniela_jensen@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Gustavo Fricke</name>
      <address>
        <city>Viña del Mar</city>
        <state>Valparaíso</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose I Vargas, MD</last_name>
      <phone>62473415</phone>
      <phone_ext>+56 9</phone_ext>
      <email>jivargasd@icloud.com</email>
    </contact>
    <contact_backup>
      <last_name>Daniela Jensen, MD</last_name>
      <phone>62473409</phone>
      <phone_ext>+56 9</phone_ext>
      <email>daniela_jensen@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jose I Vargas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Jensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Fuster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valeska Sarmiento</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2013</study_first_submitted>
  <study_first_submitted_qc>December 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2013</study_first_posted>
  <last_update_submitted>December 10, 2017</last_update_submitted>
  <last_update_submitted_qc>December 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad de Valparaiso</investigator_affiliation>
    <investigator_full_name>Felipe Martinez</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Primary Prevention</keyword>
  <keyword>Immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

